Statins more than cholesterol lowering agents in Alzheimer disease: Their pleiotropic functions as potential therapeutic targets

Biochemical Pharmacology

Volumn 88, Issue 4, 2014, Pages 605-616

  Barone, Eugenio ^a,c   Di Domenico, Fabio ^b   Butterfield, D Allan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c EPFL   (Switzerland)

Author keywords

Alzheimer disease; Biliverdin reductase; Cognition; Heme oxygenase; Oxidative stress; Statin

Indexed keywords

ATORVASTATIN; BILIVERDIN; HEME OXYGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; DEMENTIA; DRUG BIOAVAILABILITY; DRUG HALF LIFE; HUMAN; MAXIMUM PLASMA CONCENTRATION; NITROSATIVE STRESS; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

ALZHEIMER DISEASE; BILIVERDIN REDUCTASE; COGNITION; HEME OXYGENASE; OXIDATIVE STRESS; STATIN;

ALZHEIMER DISEASE; ANTICHOLESTEREMIC AGENTS; HEME OXYGENASE (DECYCLIZING); HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NITROSATION; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84897954198     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.10.030     Document Type: Review

References (160)

1. H.W. Querfurth, and F.M. LaFerla Alzheimer's disease N Engl J Med 362 2010 329 344
2. N. Kandiah, and H.H. Feldman Therapeutic potential of statins in Alzheimer's disease J Neurol Sci 283 2009 230 234
3. H. Jick, G.L. Zornberg, S.S. Jick, S. Seshadri, and D.A. Drachman Statins and the risk of dementia Lancet 356 2000 1627 1631
4. T. Kurata, K. Miyazaki, M. Kozuki, V.L. Panin, N. Morimoto, and Y. Ohta et al. Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice Brain Res 1371 2011 161 170
5. M.P. Murphy, J. Morales, T.L. Beckett, G. Astarita, D. Piomelli, and A. Weidner et al. Changes in cognition and amyloid-beta processing with long term cholesterol reduction using atorvastatin in aged dogs J Alzheimers Dis 22 2010 135 150
6. E. Barone, G. Cenini, F. Di Domenico, S. Martin, R. Sultana, and C. Mancuso et al. Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action Pharmacol Res 63 2011 172 180
7. D.A. Butterfield, E. Barone, and C. Mancuso Cholesterol-independent neuroprotective and neurotoxic activities of statins: Perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders Pharmacol Res 64 2011 180 186
8. B. McGuinness, J. O'Hare, D. Craig, R. Bullock, R. Malouf, and P. Passmore Statins for the treatment of dementia Cochrane Database Syst Rev 2010 CD007514
9. C.Y. Wang, P.Y. Liu, and J.K. Liao Pleiotropic effects of statin therapy: molecular mechanisms and clinical results Trends Mol Med 14 2008 37 44
10. J.K. Liao, and U. Laufs Pleiotropic effects of statins Annu Rev Pharmacol Toxicol 45 2005 89 118 (Pubitemid 40261799)
11. D.A. Butterfield Atorvastatin and Abeta(1-40): not as simple as cholesterol reduction in brain and relevance to Alzheimer disease Exp Neurol 228 2011 15 18
12. Y. Shitara, and Y. Sugiyama Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions Pharmacol Ther 112 2006 71 105 (Pubitemid 44301483)
13. T.P. Bersot Drug therapy for hypercholesterolemia and dyslipidemia L.B. Laurence, Goodman and Gilman's, the pharmacological basis of therapeutics 2011 McGraw-Hill New York, NY 877 908
14. M. Law, and A.R. Rudnicka Statin safety: a systematic review Am J Cardiol 97 2006 52C 60C
15. R. Ricciarelli, E. Canepa, B. Marengo, U.M. Marinari, G. Poli, and M.A. Pronzato et al. Cholesterol and Alzheimer's disease: a still poorly understood correlation IUBMB Life 64 2012 931 935
16. T. Silva, J. Teixeira, F. Remiao, and F. Borges Alzheimer's disease, cholesterol, and statins: the junctions of important metabolic pathways Angew Chem Int Ed Engl 52 2013 1110 1121
17. N.E. Shepardson, G.M. Shankar, and D.J. Selkoe Cholesterol level and statin use in Alzheimer disease II. Review of human trials and recommendations Arch Neurol-Chicago 68 2011 1385 1392
18. N.E. Shepardson, G.M. Shankar, and D.J. Selkoe Cholesterol level and statin use in Alzheimer Disease I. Review of epidemiological and preclinical studies Arch Neurol-Chicago 68 2011 1239 1244
19. A. Sanchez-Ferro, J. Benito-Leon, A.J. Mitchell, and F. Bermejo-Pareja A review of the potential therapeutic role of statins in the treatment of Alzheimer's disease: current research and opinion Neuropsych Dis Treat 9 2013 55 63
20. D.L. Sparks Alzheimer disease statins in the treatment of Alzheimer disease Nat Rev Neurol 7 2011 662 663
21. K. Rockwood Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease Acta Neurol Scand 114 2006 71 77 (Pubitemid 44015228)
22. B. Wolozin, W. Kellman, P. Ruosseau, G.G. Celesia, and G. Siegel Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3- methyglutaryl coenzyme A reductase inhibitors Arch Neurol 57 2000 1439 1443
23. L. Hajjar, J. Schumpert, V. Hirth, D. Wieland, and G.P. Eleazer The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment J Gerontol A-Biol 57 2002 M414 M418
24. K. Rockwood, S. Kirkland, D.B. Hogan, C. MacKnight, H. Merry, and R. Verreault et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people Arch Neurol 59 2002 223 227 (Pubitemid 34240938)
25. G. Li, E.B. Larson, J.A. Sonnen, J.B. Shofer, E.C. Petrie, A. Schantz, E.R. Peskind, M.A. Raskind, J.C. Breitner, and T.J. Montine Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease Neurology 69 2007 875 885
26. D.L. Sparks, R.J. Kryscio, D.J. Connor, M.N. Sabbagh, L.M. Sparks, and Y.S. Lin et al. Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort Neurodegener Dis 7 2010 183 186
27. D.L. Sparks, R.J. Kryscio, M.N. Sabbagh, D.J. Connor, L.M. Sparks, and C. Liebsack Reduced risk of incident AD with elective statin use in a clinical trial cohort Curr Alzheimer Res 5 2008 416 421
28. C. Cramer, M.N. Haan, S. Galea, K.M. Langa, and J.D. Kalbfleisch Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study Neurology 71 2008 344 350
29. M.D. Haag, A. Hofman, P.J. Koudstaal, B.H. Stricker, and M.M. Breteler Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study J Neurol Neurosurg Psychiatry 80 2009 13 17
30. E.G. Rodriguez, H.H. Dodge, M.A. Birzescu, G.P. Stoehr, and M. Ganguli Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study J Am Geriatr Soc 50 2002 1852 1856 (Pubitemid 35291730)
31. P.P. Zandi, D.L. Sparks, A.S. Khachaturian, J. Tschanz, M. Norton, and M. Steinberg et al. Do statins reduce risk of incident dementia and Alzheimer disease. The Cache County Study Arch Gen Psychiatry 62 2005 217 224 (Pubitemid 40189139)
32. T.D. Rea, J.C. Breitner, B.M. Psaty, A.L. Fitzpatrick, O.L. Lopez, and A.B. Newman et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study Arch Neurol 62 2005 1047 1051 (Pubitemid 41043724)
33. Z. Arvanitakis, J.A. Schneider, R.S. Wilson, J.L. Bienias, J.F. Kelly, and D.A. Evans et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology Neurology 70 2008 1795 1802 (Pubitemid 351653958)
34. D.L. Sparks, J. Lopez, D. Connor, M. Sabbagh, J. Seward, and P. Browne et al. A position paper: based on observational data indicating an increased rate of altered blood chemistry requiring withdrawal from the Alzheimer's Disease Cholesterol-Lowering Treatment Trial (ADCLT) J Mol Neurosci 20 2003 407 410 (Pubitemid 38146999)
35. D.L. Sparks, D.J. Connor, M.N. Sabbagh, R.B. Petersen, J. Lopez, and P. Browne Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial Acta Neurol Scand Suppl 185 2006 3 7 (Pubitemid 44015218)
36. D.L. Sparks, S. Petanceska, M. Sabbagh, D. Connor, H. Soares, and C. Adler et al. Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT) Curr Alzheimer Res 2 2005 527 539 (Pubitemid 41709390)
37. R.G. Riekse, G. Li, E.C. Petrie, J.B. Leverenz, D. Vavrek, and S. Vuletic et al. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid J Alzheimers Dis 10 2006 399 406
38. R.G. Riekse, W. Hazzard, J. Leverenz, W. Kelly, P. Boorkman, and B. Lash et al. Effects of statins on Abeta in cerebrospinal fluid J Am Geriatr Soc 53 2005 S175 S
39. C.M. Carlsson, C.E. Gleason, T.M. Hess, K.A. Moreland, H.M. Blazel, and R.L. Koscik et al. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease J Alzheimers Dis 13 2008 187 197 (Pubitemid 352038526)
40. J. Shepherd, G.J. Blauw, M.B. Murphy, E.L. Bollen, B.M. Buckley, and S.M. Cobbe et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630 (Pubitemid 35379733)
41. S. Trompet, P. van Vliet, A.J. de Craen, J. Jolles, B.M. Buckley, and M.B. Murphy et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study J Neurol 257 2010 85 90
42. G. Heart Protection Study Collaborative MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
43. H.H. Feldman, R.S. Doody, M. Kivipelto, D.L. Sparks, D.D. Waters, and R.W. Jones et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe Neurology 74 2010 956 964
44. B. McGuinness, J. O'Hare, D. Craig, R. Bullock, R. Malouf, and P. Passmore Statins for the treatment of dementia Cochrane Database Syst Rev 2010
45. A.B. Reiss, and E. Wirkowski Statins in neurological disorders: mechanisms and therapeutic value ScientificWorldJournal 9 2009 1242 1259
46. M. Sano, K.L. Bell, D. Galasko, J.E. Galvin, R.G. Thomas, and C.H. van Dyck et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease Neurology 77 2011 556 563
47. K.P. Padala, P.R. Padala, D.P. McNeilly, J.A. Geske, D.H. Sullivan, and J.F. Potter The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: a prospective withdrawal and rechallenge pilot study Am J Geriatr Pharmacother 10 2012 296 302
48. J.D. Orr Statins in the spectrum of neurologic disease Curr Atheroscler Rep 10 2008 11 18 (Pubitemid 351385594)
49. T. Wallerath, D. Poleo, H. Li, and U. Forstermann Red wine increases the expression of human endothelial nitric oxide synthase: a mechanism that may contribute to its beneficial cardiovascular effects J Am Coll Cardiol 41 2003 471 478 (Pubitemid 36164505)
50. U. Landmesser, F. Bahlmann, M. Mueller, S. Spiekermann, N. Kirchhoff, and S. Schulz et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans Circulation 111 2005 2356 2363 (Pubitemid 40647072)
51. U. Laufs, V. La Fata, J. Plutzky, and J.K. Liao Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors Circulation 97 1998 1129 1135 (Pubitemid 28152885)
52. Y. Kureishi, Z. Luo, I. Shiojima, A. Bialik, D. Fulton, and D.J. Lefer et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals Nat Med 6 2000 1004 1010
53. V.E. Miron, S. Rajasekharan, A.A. Jarjour, S.S. Zamvil, T.E. Kennedy, and J.P. Antel Simvastatin regulates oligodendroglial process dynamics and survival Glia 55 2007 130 143 (Pubitemid 46036460)
54. G.P. Littarru, and P. Langsjoen Coenzyme Q10 and statins: biochemical and clinical implications Mitochondrion 7 Suppl. 2007 S168 S174 (Pubitemid 46712232)
55. L. Marcoff, and P.D. Thompson The role of coenzyme Q10 in statin-associated myopathy: a systematic review J Am Coll Cardiol 49 2007 2231 2237 (Pubitemid 46856819)
56. M.I. Cerezo-Guisado, N. Garcia-Roman, L.J. Garcia-Marin, A. Alvarez-Barrientos, M.J. Bragado, and M.J. Lorenzo Lovastatin inhibits the extracellular-signal-regulated kinase pathway in immortalized rat brain neuroblasts Biochem J 401 2007 175 183 (Pubitemid 46114611)
57. M.S. Qiu, A.F. Pitts, T.R. Winters, and S.H. Green ras isoprenylation is required for ras-induced but not for NGF-induced neuronal differentiation of PC12 cells J Cell Biol 115 1991 795 808 (Pubitemid 21909931)
58. O. Maier, J. De Jonge, A. Nomden, D. Hoekstra, and W. Baron Lovastatin induces the formation of abnormal myelin-like membrane sheets in primary oligodendrocytes Glia 57 2009 402 413
59. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 2002 353 356 (Pubitemid 34790756)
60. D.A. Butterfield, J. Drake, C. Pocernich, and A. Castegna Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide Trends Mol Med 7 2001 548 554 (Pubitemid 33127140)
61. T.A. Clark, H.P. Lee, R.K. Rolston, X. Zhu, M.W. Marlatt, and R.J. Castellani et al. Oxidative stress and its implications for future treatments and management of Alzheimer disease Int J Biomed Sci 6 2010 225 227
62. Z. Cai, B. Zhao, and A. Ratka Oxidative stress and beta-amyloid protein in Alzheimer's disease Neuromol Med 13 2011 223 250
63. P.H. Axelsen, H. Komatsu, and I.V. Murray Oxidative stress and cell membranes in the pathogenesis of Alzheimer's disease Physiology (Bethesda) 26 2011 54 69
64. D.A. Butterfield, and C.M. Lauderback Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress Free Radic Biol Med 32 2002 1050 1060 (Pubitemid 34603342)
65. D.A. Butterfield, T. Reed, S.F. Newman, and R. Sultana Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment Free Radic Biol Med 43 2007 658 677 (Pubitemid 47102132)
66. H. Kurinami, N. Sato, M. Shinohara, D. Takeuchi, S. Takeda, and M. Shimamura et al. Prevention of amyloid beta-induced memory impairment by fluvastatin, associated with the decrease in amyloid beta accumulation and oxidative stress in amyloid beta injection mouse model Int J Mol Med 21 2008 531 537
67. X.K. Tong, N. Nicolakakis, P. Fernandes, B. Ongali, J. Brouillette, and R. Quirion et al. Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice Neurobiol Dis 35 2009 406 414
68. T.C. Piermartiri, C.P. Figueiredo, D. Rial, F.S. Duarte, S.C. Bezerra, and G. Mancini et al. Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-beta(1-40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage Exp Neurol 226 2010 274 284
69. N.E. Shepardson, G.M. Shankar, and D.J. Selkoe Cholesterol level and statin use in Alzheimer disease. II. Review of human trials and recommendations Arch Neurol 68 2011 1385 1392
70. K.M. Thelen, K.M. Rentsch, U. Gutteck, M. Heverin, M. Olin, and U. Andersson et al. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin J Pharmacol Exp Ther 316 2006 1146 1152 (Pubitemid 43345288)
71. E.M. Johnstone, M.O. Chaney, F.H. Norris, R. Pascual, and S.P. Little Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis Brain Res Mol Brain Res 10 1991 299 305
72. R. Torp, E. Head, and C.W. Cotman Ultrastructural analyses of beta-amyloid in the aged dog brain: Neuronal beta-amyloid is localized to the plasma membrane Prog Neuropsychopharmacol Biol Psychiatry 24 2000 801 810 (Pubitemid 30640160)
73. R. Torp, E. Head, N.W. Milgram, F. Hahn, O.P. Ottersen, and C.W. Cotman Ultrastructural evidence of fibrillar β-amyloid associated with neuronal membranes in behaviorally characterized aged dog brains Neuroscience 93 2000 495 506 (Pubitemid 30136315)
74. R. Torp, O.P. Ottersen, C.W. Cotman, and E. Head Identification of neuronal plasma membrane microdomains that colocalize beta-amyloid and presenilin: implications for beta-amyloid precursor protein processing Neuroscience 120 2003 291 300 (Pubitemid 37288767)
75. C.W. Cotman, and E. Head The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches J Alzheimers Dis 15 2008 685 707
76. M. Perluigi, R. Coccia, and D.A. Butterfield 4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: a toxic combination illuminated by redox proteomics studies Antioxid Redox Signal 17 2012 1590 1609
77. D.A. Butterfield, T. Reed, and R. Sultana Roles of 3-nitrotyrosine- and 4-hydroxynonenal-modified brain proteins in the progression and pathogenesis of Alzheimer's disease Free Radic Res 45 2011 59 72
78. D.A. Butterfield, M.L. Bader Lange, and R. Sultan Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease Biochim Biophys Acta 1801 2010 924 929
79. J. Vaya, and H.M. Schipper Oxysterols, cholesterol homeostasis, and Alzheimer disease J Neurochem 102 2007 1727 1737 (Pubitemid 47329280)
80. J.H. Han, Y.J. Kim, E.S. Han, and C.S. Lee Prevention of 7-ketocholesterol-induced mitochondrial damage and cell death by calmodulin inhibition Brain Res 1137 2007 11 19 (Pubitemid 46240061)
81. S.R. Panini, L. Yang, A.E. Rusinol, M.S. Sinensky, J.V. Bonventre, and C.C. Leslie Arachidonate metabolism and the signaling pathway of induction of apoptosis by oxidized LDL/oxysterol J Lipid Res 42 2001 1678 1686 (Pubitemid 33020101)
82. A. Trousson, S. Bernard, P.X. Petit, P. Liere, A. Pianos, and K. El Hadri et al. 25-Hydroxycholesterol provokes oligodendrocyte cell line apoptosis and stimulates the secreted phospholipase A2 type IIA via LXR beta and PXR J Neurochem 109 2009 945 958
83. K. Kathir, J.M. Dennis, K.D. Croft, T.A. Mori, A.K. Lau, and M.R. Adams et al. Equivalent lipid oxidation profiles in advanced atherosclerotic lesions of carotid endarterectomy plaques obtained from symptomatic type 2 diabetic and nondiabetic subjects Free Radic Biol Med 49 2010 481 486
84. H. Larsson, Y. Bottiger, L. Iuliano, and U. Diczfalusy In vivo interconversion of 7beta-hydroxycholesterol and 7-ketocholesterol, potential surrogate markers for oxidative stress Free Radic Biol Med 43 2007 695 701 (Pubitemid 47102124)
85. A. Berthier, S. Lemaire-Ewing, C. Prunet, S. Monier, A. Athias, and G. Bessede et al. Involvement of a calcium-dependent dephosphorylation of BAD associated with the localization of Trpc-1 within lipid rafts in 7-ketocholesterol-induced THP-1 cell apoptosis Cell Death Differ 11 2004 897 905 (Pubitemid 39139748)
86. B.S. Kumar, B.C. Chung, Y.J. Lee, H.J. Yi, B.H. Lee, and B.H. Jung A GC/MS-based simultaneous quantitative analytical method for urinary oxysterols and bile acids in rats Anal Biochem 408 2012 242 252
87. K.M. Thelen, R. Laaksonen, H. Paiva, T. Lehtimaki, and D. Lutjohann High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels J Clin Pharmacol 46 2006 812 816 (Pubitemid 43882805)
88. E.G. Bliznakov, and D.J. Wilkins Biochemical and clinical consequences of inhibiting coenzyme Q(10) biosynthesis by lipid-lowering HMG-CoA reductase inhibitors (statins): a critical overview Adv Ther 15 1998 218 228 (Pubitemid 28454901)
89. A.M. James, R.A. Smith, and M.P. Murphy Antioxidant and prooxidant properties of mitochondrial Coenzyme Q Arch Biochem Biophys 423 2004 47 56 (Pubitemid 38198212)
90. C. Schmelzer, I. Lindner, G. Rimbach, P. Niklowitz, T. Menke, and F. Doring Functions of coenzyme Q10 in inflammation and gene expression Biofactors 32 2008 179 183
91. R.A. Willis, K. Folkers, J.L. Tucker, C.Q. Ye, L.J. Xia, and H. Tamagawa Lovastatin decreases coenzyme Q levels in rats Proc Natl Acad Sci U S A 87 1990 8928 8930 (Pubitemid 120007622)
92. K. Satoh, A. Yamato, T. Nakai, K. Hoshi, and K. Ichihara Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts Br J Pharmacol 116 1995 1894 1898
93. T. Rundek, A. Naini, R. Sacco, K. Coates, and S. DiMauro Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke Arch Neurol 61 2004 889 892 (Pubitemid 38747328)
94. M. Spindler, M.F. Beal, and C. Henchcliffe Coenzyme Q10 effects in neurodegenerative disease Neuropsychiatr Dis Treat 5 2009 597 610
95. M. Turunen, J. Olsson, and G. Dallner Metabolism and function of coenzyme Q Biochim Biophys Acta 1660 2004 171 199 (Pubitemid 38125244)
96. E. Head, V.N. Nukala, K.A. Fenoglio, B.A. Muggenburg, C.W. Cotman, and P.G. Sullivan Effects of age, dietary, and behavioral enrichment on brain mitochondria in a canine model of human aging Exp Neurol 220 2009 171 176
97. S.B. Martin, G. Cenini, E. Barone, A.L. Dowling, C. Mancuso, and D.A. Butterfield et al. Coenzyme Q10 and cognition in atorvastatin treated dogs Neurosci Lett 501 2011 92 95
98. P.H. Langsjoen, J.O. Langsjoen, A.M. Langsjoen, and L.A. Lucas Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation Biofactors 25 2005 147 152 (Pubitemid 44070842)
99. M.D. Maines The heme oxygenase system: a regulator of second messenger gases Annu Rev Pharmacool Toxicol 37 1997 517 554 (Pubitemid 27238886)
100. C. Mancuso, and E. Barone The heme oxygenase/biliverdin reductase pathway in drug research and development Curr Drug Metab 10 2009 579 594
101. E. Barone, F. Di Domenico, C. Mancuso, and D.A. Butterfield The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation Neurobiol Dis 62C 2013 144 159
102. J. Kapitulnik, and M.D. Maines Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin Trends Pharmacol Sci 30 2009 129 137
103. M.D. Maines New insights into biliverdin reductase functions: linking heme metabolism to cell signaling Physiology (Bethesda) 20 2005 382 389 (Pubitemid 41812421)
104. P.J. Pereira, S. Macedo-Ribeiro, A. Parraga, R. Perez-Luque, O. Cunningham, and K. Darcy et al. Structure of human biliverdin IXbeta reductase, an early fetal bilirubin IXbeta producing enzyme Nat Struct Biol 8 2001 215 220 (Pubitemid 32180045)
105. R. Stocker Antioxidant activities of bile pigments Antioxid Redox Signal 6 2004 841 849 (Pubitemid 39237937)
106. E. Barone, S. Trombino, R. Cassano, A. Sgambato, B. De Paola, and E. Di Stasio et al. Characterization of the S-denitrosylating activity of bilirubin J Cell Mol Med 13 2009 2365 2375
107. H.F. Poon, V. Calabrese, G. Scapagnini, and D.A. Butterfield Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress J Gerontol Ser A, Biol Sci Med Sci 59 2004 478 493 (Pubitemid 38649940)
108. C. Mancuso, P. Navarra, and P. Preziosi Roles of nitric oxide, carbon monoxide, and hydrogen sulfide in the regulation of the hypothalamic-pituitary- adrenal axis J Neurochem 113 2010 563 575
109. C. Mancuso, G. Pani, and V. Calabrese Bilirubin: an endogenous scavenger of nitric oxide and reactive nitrogen species Redox Rep 11 2006 207 213 (Pubitemid 44741627)
110. V. Calabrese, C. Mancuso, M. Calvani, E. Rizzarelli, D.A. Butterfield, and A.M. Stella Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity Nat Rev Neurosci 8 2007 766 775 (Pubitemid 47462116)
111. C. Mancuso, G. Scapagini, D. Curro, A.M. Giuffrida Stella, C. De Marco, and D.A. Butterfield et al. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders Front Biosci 12 2007 1107 1123 (Pubitemid 46846882)
112. V. Calabrese, R. Sultana, G. Scapagnini, E. Guagliano, M. Sapienza, and R. Bella et al. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease Antioxid Redox Signal 8 2006 1975 1986 (Pubitemid 46489625)
113. W.R. Markesbery Oxidative stress hypothesis in Alzheimer's disease Free Radic Biol Med 23 1997 134 147 (Pubitemid 27217017)
114. M.A. Smith, G. Perry, and W.A. Pryor Causes and consequences of oxidative stress in Alzheimer's disease Free Radic Biol Med 32 2002 1049 (Pubitemid 34603341)
115. N. Lerner-Marmarosh, J. Shen, M.D. Torno, A. Kravets, Z. Hu, and M.D. Maines Human biliverdin reductase: a member of the insulin receptor substrate family with serine/threonine/tyrosine kinase activity Proc Natl Acad Sci U S A 102 2005 7109 7114 (Pubitemid 40696342)
116. N. Lerner-Marmarosh, T. Miralem, P.E. Gibbs, and M.D. Maines Human biliverdin reductase is an ERK activator; hBVR is an ERK nuclear transporter and is required for MAPK signaling Proc Natl Acad Sci U S A 105 2008 6870 6875 (Pubitemid 351754497)
117. C. Tudor, N. Lerner-Marmarosh, Y. Engelborghs, P.E. Gibbs, and M.D. Maines Biliverdin reductase is a transporter of haem into the nucleus and is essential for regulation of HO-1 gene expression by haematin Biochem J 413 2008 405 416
118. M.D. Maines Biliverdin reductase: PKC interaction at the cross-talk of MAPK and PI3K signaling pathways Antioxid Redox Signal 9 2007 2187 2195 (Pubitemid 350059025)
119. F. Di Domenico, M. Perluigi, and E. Barone Biliverdin reductase-A correlates with inducible nitric oxide synthasein in atorvastatin treated aged canine brain Neural Reg Res 8 2013 1925 1937
120. A.C. Newton Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions Chem Rev 101 2001 2353 2364 (Pubitemid 35373023)
121. F.G. Whitby, J.D. Phillips, C.P. Hill, W. McCoubrey, and M.D. Maines Crystal structure of a biliverdin IXalpha reductase enzyme-cofactor complex J Mol Biol 319 2002 1199 1210 (Pubitemid 34729428)
122. Z. Ahmad, M. Salim, and M.D. Maines Human biliverdin reductase is a leucine zipper-like DNA-binding protein and functions in transcriptional activation of heme oxygenase-1 by oxidative stress J Biol Chem 277 2002 9226 9232 (Pubitemid 34953003)
123. M.G. Myers Jr., Y. Zhang, G.A. Aldaz, T. Grammer, E.M. Glasheen, and L. Yenush et al. YMXM motifs and signaling by an insulin receptor substrate 1 molecule without tyrosine phosphorylation sites Mol Cell Biol 16 1996 4147 4155 (Pubitemid 26251214)
124. T. Hunter, and J.A. Cooper Protein-tyrosine kinases Annu Rev Biochem 54 1985 897 930 (Pubitemid 15073667)
125. P.E. Gibbs, C. Tudor, and M.D. Maines Biliverdin reductase: more than a namesake - the reductase, its peptide fragments, and biliverdin regulate activity of the three classes of protein kinase C Front Pharmacol 3 2012 31
126. N. Lerner-Marmarosh, T. Miralem, P.E. Gibbs, and M.D. Maines Regulation of TNF-alpha-activated PKC-zeta signaling by the human biliverdin reductase: identification of activating and inhibitory domains of the reductase FASEB J 21 2007 3949 3962 (Pubitemid 350232352)
127. T. Miralem, P.E. Gibbs, F. Revert, J. Saus, and M.D. Maines Human biliverdin reductase suppresses Goodpasture antigen-binding protein (GPBP) kinase activity: the reductase regulates tumor necrosis factor-alpha-NF-kappaB- dependent GPBP expression J Biol Chem 285 2010 12551 12558
128. P.E. Gibbs, T. Miralem, N. Lerner-Marmarosh, C. Tudor, and M.D. Maines Formation of ternary complex of human biliverdin reductase-protein kinase Cdelta-ERK2 protein is essential for ERK2-mediated activation of Elk1 protein, nuclear factor-kappaB, and inducible nitric-oxidase synthase (iNOS) J Biol Chem 287 2012 1066 1079
129. J.R. Hascalovici, J. Vaya, S. Khatib, C.A. Holcroft, H. Zukor, and W. Song et al. Brain sterol dysregulation in sporadic AD and MCI: relationship to heme oxygenase-1 J Neurochem 110 2009 1241 1253
130. A. Takeda, Y. Itoyama, T. Kimpara, X. Zhu, J. Avila, and B.E. Dwyer et al. Heme catabolism and heme oxygenase in neurodegenerative disease Antioxid Redox Signal 6 2004 888 894 (Pubitemid 39237942)
131. M.A. Smith, P.L. Harris, L.M. Sayre, and G. Perry Iron accumulation in Alzheimer disease is a source of redox-generated free radicals Proc Natl Acad Sci U S A 94 1997 9866 9868 (Pubitemid 27408156)
132. H.M. Schipper Heme oxygenase-1 in Alzheimer disease: a tribute to Moussa Youdim J Neural Transm 118 2011 381 387
133. F. Di Domenico, J.B. Owen, R. Sultana, R.A. Sowell, M. Perluigi, and C. Cini et al. The wheat germ agglutinin-fractionated proteome of subjects with Alzheimer's disease and mild cognitive impairment hippocampus and inferior parietal lobule: Implications for disease pathogenesis and progression J Neurosci Res 88 2010 3566 3577
134. E. Barone, F. Di Domenico, G. Cenini, R. Sultana, R. Coccia, and P. Preziosi et al. Oxidative and nitrosative modifications of biliverdin reductase-A in the brain of subjects with Alzheimer's disease and amnestic mild cognitive impairment J Alzheimers Dis 25 2011 623 633
135. E. Barone, F. Di Domenico, G. Cenini, R. Sultana, C. Cini, and P. Preziosi et al. Biliverdin reductase - a protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment Biochim Biophys Acta 1812 2011 480 487
136. F. Di Domenico, E. Barone, C. Mancuso, M. Perluigi, A. Cocciolo, and P. Mecocci et al. HO-1/BVR-a system analysis in plasma from probable Alzheimer's disease and mild cognitive impairment subjects: a potential biochemical marker for the prediction of the disease J Alzheimers Dis 32 2012 277 289
137. E. Barone, F. Di Domenico, R. Sultana, R. Coccia, C. Mancuso, and M. Perluigi et al. Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment Free Radic Biol Med 52 2012 2292 2301
138. C. Mueller, W. Zhou, A. Vanmeter, M. Heiby, S. Magaki, and M.M. Ross et al. The heme degradation pathway is a promising serum biomarker source for the early detection of Alzheimer's disease J Alzheimers Dis 19 2010 1081 1091
139. E.M. Franklin, S. Browne, A.M. Horan, K. Inomata, M.A. Hammam, and H. Kinoshita et al. The use of synthetic linear tetrapyrroles to probe the verdin sites of human biliverdin-IXalpha reductase and human biliverdin-IXbeta reductase FEBS J 276 2009 4405 4413
140. C. Li, P. Hossieny, B.J. Wu, A. Qawasmeh, K. Beck, and R. Stocker Pharmacologic induction of heme oxygenase-1 Antioxid Redox Signal 9 2007 2227 2239 (Pubitemid 350059011)
141. M. Hsu, L. Muchova, I. Morioka, R.J. Wong, H. Schroder, and D.K. Stevenson Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo Biochem Biophys Res Commun 343 2006 738 744
142. I.R. Lai, K.J. Chang, H.W. Tsai, and C.F. Chen Pharmacological preconditioning with simvastatin protects liver from ischemia-reperfusion injury by heme oxygenase-1 induction Transplantation 85 2008 732 738
143. E. Barone, C. Mancuso, F. Di Domenico, R. Sultana, M.P. Murphy, and E. Head et al. Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease J Neurochem 120 2012 135 146
144. C.H. Hsieh, C.S. Rau, M.W. Hsieh, Y.C. Chen, S.F. Jeng, and T.H. Lu et al. Simvastatin-induced heme oxygenase-1 increases apoptosis of Neuro 2A cells in response to glucose deprivation Toxicol Sci 101 2008 112 121
145. C.H. Hsieh, S.F. Jeng, M.W. Hsieh, Y.C. Chen, C.S. Rau, and T.H. Lu et al. Statin-induced heme oxygenase-1 increases NF-kappaB activation and oxygen radical production in cultured neuronal cells exposed to lipopolysaccharide Toxicol Sci 102 2008 150 159
146. M. Kannan, J.R. Steinert, I.D. Forsythe, A.G. Smith, and T. Chernova Mevastatin accelerates loss of synaptic proteins and neurite degeneration in aging cortical neurons in a heme-independent manner Neurobiol Aging 31 2010 1543 1553
147. D.A. Butterfield, E. Barone, F. Di Domenico, G. Cenini, R. Sultana, and M.P. Murphy et al. Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain Int J Neuropsychopharmacol 15 2012 981 987
148. M. Zhuo, S.A. Small, E.R. Kandel, and R.D. Hawkins Nitric oxide and carbon monoxide produce activity-dependent long-term synaptic enhancement in hippocampus Science 260 1993 1946 1950 (Pubitemid 23258276)
149. S.C. Lu Regulation of glutathione synthesis Mol Aspects Med 30 2009 42 59
150. E.J. Collinson, S. Wimmer-Kleikamp, S.K. Gerega, Y.H. Yang, C.R. Parish, and I.W. Dawes et al. The yeast homolog of heme oxygenase-1 affords cellular antioxidant protection via the transcriptional regulation of known antioxidant genes J Biol Chem 286 2011 2205 2214
151. E. Head, R. McCleary, F.F. Hahn, N.W. Milgram, and C.W. Cotman Region-specific age at onset of beta-amyloid in dogs Neurobiol Aging 21 2000 89 96 (Pubitemid 30224790)
152. T.C. Sacktor How does PKMzeta maintain long-term memory Nat Rev Neurosci 12 2011 9 15
153. R. Stocker, A.N. Glazer, and B.N. Ames Antioxidant activity of albumin-bound bilirubin Proc Natl Acad Sci U S A 84 1987 5918 5922 (Pubitemid 17130420)
154. R. Stocker, Y. Yamamoto, A.F. McDonagh, A.N. Glazer, and B.N. Ames Bilirubin is an antioxidant of possible physiological importance Science 235 1987 1043 1046 (Pubitemid 17049750)
155. S. Dore, M. Takahashi, C.D. Ferris, R. Zakhary, L.D. Hester, and D. Guastella et al. Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury Proc Natl Acad Sci U S A 96 1999 2445 2450 (Pubitemid 29117935)
156. C. Mancuso, C. Capone, S.C. Ranieri, S. Fusco, V. Calabrese, and M.L. Eboli et al. Bilirubin as an endogenous modulator of neurotrophin redox signaling J Neurosci Res 86 2008 2235 2249
157. A. Suzuki, H. Fukushima, T. Mukawa, H. Toyoda, L.J. Wu, and M.G. Zhao et al. Upregulation of CREB-mediated transcription enhances both short- and long-term memory J Neurosci 31 2011 8786 8802
158. R. Vassar, D.M. Kovacs, R. Yan, and P.C. Wong The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential J Neurosci 29 2009 12787 12794
159. T. Wahle, K. Prager, N. Raffler, C. Haass, M. Famulok, and J. Walter GGA proteins regulate retrograde transport of BACE1 from endosomes to the trans-Golgi network Mol Cell Neurosci 29 2005 453 461 (Pubitemid 40799217)
160. G. Tesco, Y.H. Koh, E.L. Kang, A.N. Cameron, S. Das, and M. Sena-Esteves et al. Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity Neuron 54 2007 721 737 (Pubitemid 46843521)